Is Udg Healthcare Public Limited Company (LON:UDG) Finally Worth Your Time? What Does Barclays Think?

May 17, 2018 - By Margaret Downey

UDG Healthcare plc (LON:UDG) Logo

Why Has Barclays Given Udg Healthcare Public Limited Company (LON:UDG) a GBX 875.00 Price Target

London: Udg Healthcare Public Limited Company (LON:UDG) coverage was initiated with a key ‘Equal-weight’ rating as well as a GBX 875.00 target price per share at Barclays. The target by Barclays would indicate downside of -5.91 % from the stock close price.

UDG Healthcare plc (LON:UDG) Ratings Coverage

Among 8 analysts covering UDG Healthcare PLC (LON:UDG), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. UDG Healthcare PLC has GBX 1100 highest and GBX 765 lowest target. GBX 869.50’s average target is -6.30% below currents GBX 928 stock price. UDG Healthcare PLC had 20 analyst reports since November 28, 2017 according to SRatingsIntel. The company was maintained on Thursday, May 17 by Numis Securities. The firm has “Add” rating by Peel Hunt given on Tuesday, November 28. The rating was maintained by Stifel Nicolaus with “Hold” on Thursday, November 30. The firm earned “Buy” rating on Wednesday, February 7 by Liberum Capital. Peel Hunt maintained UDG Healthcare plc (LON:UDG) on Friday, February 23 with “Add” rating. The firm has “Add” rating given on Wednesday, April 4 by Peel Hunt. N+1 Singer maintained the stock with “Hold” rating in Wednesday, February 7 report. The firm earned “Add” rating on Thursday, February 1 by Peel Hunt. The stock of UDG Healthcare plc (LON:UDG) has “Buy” rating given on Tuesday, May 1 by Peel Hunt. On Tuesday, November 28 the stock rating was maintained by N+1 Singer with “Hold”.

The stock increased 0.22% or GBX 2 during the last trading session, reaching GBX 928. About 847,545 shares traded. UDG Healthcare plc (LON:UDG) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company has market cap of 2.31 billion GBP. The firm operates through three divisions: Ashfield, Sharp, and Aquilant. It has a 32.22 P/E ratio. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: